NCT04818398 - Study of Single-Ascending Doses of DS-6016a in Healthy Japanese Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 1, 2021

Primary Completion Date

December 24, 2021

Study Completion Date

July 26, 2022

Conditions

Fibrodysplasia Ossificans Progressiva

Interventions

DRUG

DS-6016a

DS-6016a will be administered as a single subcutaneous injection into the upper arm, upper part of the thigh, or abdominal wall

DRUG

Placebo

Placebo will be administered as a single subcutaneous injection into the upper arm, upper part of the thigh, or abdominal wall

Trial Locations (1)

Medical Corporation Heishinkai OPHAC Hospital, Osaka